Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EryDex for Neurological Symptoms in Ataxia Telangiectasia
NCT02770807Phase 3Completed
- Sponsor
- IRulya Therapeutics
- Start
- Mar 2017
- Primary completion
- May 2021
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 12
01
Overview
A Phase 3 trial of EryDex in ataxia-telangiectasia (AT), sponsored by IRulya Therapeutics. Started Mar 2017; status: completed.
02
Drugs
EryDex
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT02770807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770807.